Carbapenem Resistance in India: A Systematic Review of Epidemiology, Diagnostic Strategies, and Therapeutic Approaches
BioMed Research International · 2026-01 · 2026 (1)
DOI: 10.1155/bmri/6806493 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift BioMed Research International, online erschienen am 12.08.2026. Verfasst von Akhil Kapoor und 11 weiteren Autor:innen. Beteiligte Einrichtung: Departments of Medical Oncology, Mahamana Pandit Madan Mohan Malaviya Cancer Centre and Homi Bhabha Cancer Hospital, Tata Memorial Centre, Homi Bhabh…. Hauptthemen laut MEDLINE: Carbapenems, Anti-Bacterial Agents, Gram-Negative Bacterial Infections, Gram-Negative Bacteria. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Carbapenem‐resistant gram‐negative infections pose a major public health challenge in India due to high antibiotic consumption, limited diagnostic access, and regional variation in resistance mechanisms. We systematically reviewed recent data to evaluate prevalence, diagnostics, and therapeutic strategies.
Methods
Following PRISMA 2020 guidelines, we searched PubMed, Scopus, Embase, and Google Scholar for studies (January 2019–December 2024) reporting carbapenem resistance in clinical gram‐negative isolates from India. Data on prevalence, molecular mechanisms, diagnostics, and treatment outcomes were extracted. Study quality was assessed using the Joanna Briggs Institute (JBI) Checklist.
Results
From 75 studies (> 25,000 isolates), pooled resistance rates were K. pneumoniae 42.3%, E. coli 35.6%, A. baumannii 58.9%, and P. aeruginosa 41.7%. NDM (65%) and OXA‐48‐like (20%) enzymes predominated. Only 38% of studies employed rapid molecular diagnostics. Treatment strategies included ceftazidime‐avibactam ± aztreonam, colistin‐based regimens, and cefiderocol, but outcomes were inconsistent.
Conclusions
Carbapenem resistance in India remains alarmingly high, primarily driven by NDM and OXA‐type carbapenemases. Optimised diagnostics, improved access to effective antimicrobials, robust antimicrobial stewardship, and national surveillance are critical to mitigate its growing clinical and public health impact.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Departments of Medical Oncology, Mahamana Pandit Madan Mohan Malaviya Cancer Centre and Homi Bhabha Cancer Hospital, Tata Memorial Centre, Homi Bhabha National Institute, Varanasi, India, hbni.ac.in.
- Departments of Medical Microbiology, Mahamana Pandit Madan Mohan Malaviya Cancer Centre and Homi Bhabha Cancer Hospital, Tata Memorial Centre, Homi Bhabha National Institute, Varanasi, India, hbni.ac.in.
- Departments of Medical Radiation Oncology, Mahamana Pandit Madan Mohan Malaviya Cancer Centre and Homi Bhabha Cancer Hospital, Tata Memorial Centre, Homi Bhabha National Institute, Varanasi, India, hbni.ac.in.
ORCID-Profile: Akhil Kapoor, Anuj Gupta, Bipinesh Sansar
Zitieren
APA
Kapoor, A., Gupta, A., Sansar, B., Mishra, B. K., Singh, M., Sarode, R., Bajpai, V., Singh, A., Bharti, S., Mishra, A., Chaurasia, A., & Pradhan, S. (2026). Carbapenem Resistance in India: A Systematic Review of Epidemiology, Diagnostic Strategies, and Therapeutic Approaches. BioMed Research International, 2026(1). https://doi.org/10.1155/bmri/6806493
Vancouver
Kapoor A, Gupta A, Sansar B, Mishra BK, Singh M, Sarode R, et al. Carbapenem Resistance in India: A Systematic Review of Epidemiology, Diagnostic Strategies, and Therapeutic Approaches. BioMed Research International. 2026;2026(1). doi:10.1155/bmri/6806493
BibTeX
@article{Kapoor2026,
author = {Kapoor, Akhil and Gupta, Anuj and Sansar, Bipinesh and Mishra, Bal Krishna and Singh, Madhu and Sarode, Rahul and Bajpai, Vijeta and Singh, Anil and Bharti, Sujit and Mishra, Anwita and Chaurasia, Ankita and Pradhan, Satyajit},
title = {Carbapenem Resistance in India: A Systematic Review of Epidemiology, Diagnostic Strategies, and Therapeutic Approaches},
journal = {BioMed Research International},
year = {2026},
volume = {2026},
number = {1},
doi = {10.1155/bmri/6806493}
}
EUVIMED